In earlier works, we reported a peptide variant, referred to as VGB3 that binds to both VEGFR1 and VEGFR2, thereby inhibits VEGF-driven proliferation, migration and tube formation of endothelial cells, and tumor growth and metastasis in murine 4T1 mammary carcinoma tumor model [13, 14]. This evidence concerns the gene FLT1 and neoplasm.